Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patisiran in Japanese Healthy Volunteers
NCT02053454Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of patisiran in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation at 28 days. Started Jan 2014; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT02053454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053454.